Comparative Pharmacology
Head-to-head clinical analysis: METHYLPREDNISOLONE ACETATE versus RAYOS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METHYLPREDNISOLONE ACETATE versus RAYOS.
METHYLPREDNISOLONE ACETATE vs RAYOS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methylprednisolone acetate is a synthetic glucocorticoid that binds to the glucocorticoid receptor, modulating gene expression to suppress inflammation, immune response, and adrenal function. It inhibits phospholipase A2, reduces prostaglandin and leukotriene synthesis, and decreases cytokine production.
Synthetic glucocorticoid with anti-inflammatory, immunosuppressive, and metabolic effects; binds to glucocorticoid receptor, modulating gene expression and inhibiting phospholipase A2, cytokine production, and immune cell activity.
40-80 mg intramuscular (IM) or intra-articular (IA) injection; for IM use, dose may be repeated every 1-4 weeks as needed. Maximum single IM dose: 120 mg.
Initial adult dose 5-60 mg orally once daily, adjusted based on disease severity and response. Typically administered as a single dose in the morning with food.
None Documented
None Documented
Terminal half-life: 3-3.5 hours; correlates with duration of anti-inflammatory effect due to receptor-mediated action.
2-3 hours (terminal); prolonged in hepatic impairment; circadian-timed formulation intended for once-daily morning dosing.
Renal: <10% unchanged; extensive hepatic metabolism to inactive metabolites primarily excreted renally as glucuronides and sulfates.
Renal: ~80% as inactive metabolites; fecal: ~5%; biliary: small amount.
Category D/X
Category C
Corticosteroid
Corticosteroid